• xmlui.mirage2.page-structure.header.title
    • français
    • English
  • Help
  • Login
  • Language 
    • Français
    • English
View Item 
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
  •   BIRD Home
  • LEDa (UMR CNRS 8007, UMR IRD 260)
  • LEDa : Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesTypeThis CollectionBy Issue DateAuthorsTitlesType

My Account

LoginRegister

Statistics

Most Popular ItemsStatistics by CountryMost Popular Authors
Thumbnail

Where does the value of 'value-added' pharmaceuticals come from?

Barei, Fereshteh (2016), Where does the value of 'value-added' pharmaceuticals come from?, GaBI Journal, 5, 4, p. 171-173. 10.5639/gabij.2016.0504.044

View/Open
Where does the value of.pdf (268.5Kb)
Type
Article accepté pour publication ou publié
Date
2016-11
Journal name
GaBI Journal
Volume
5
Number
4
Publisher
GaBI
Pages
171-173
Publication identifier
10.5639/gabij.2016.0504.044
Metadata
Show full item record
Author(s)
Barei, Fereshteh
Abstract (FR)
Le rôle de la science , de la découverte et de l'innovation dans les produits pharmaceutiques à valeur ajoutée n'a pas été suffisamment pris en compte. Ce terme est principalement utilisé pour définir une version améliorée des médicaments génériques. Le concept de produits pharmaceutiques à valeur ajoutée a été repris par différents groupes d'entreprises, certains visent à accroître la volonté de payer leurs produits pharmaceutiques modifiés, d'autres comme les producteurs pharmaceutiques génériques, tentent de devenir plus innovants et moins «dépendants de l'expiration des brevets» . L'optimisation des produits pharmaceutiques existants peut créer un avantage concurrentiel et renforcer la réputation et la crédibilité des sociétés pharmaceutiques génériques.
Abstract (EN)
The role of sound science, discovery, and innovation in value-added pharmaceuticals has not been sufficiently considered. This term is mainly used to define improved version of generic drugs. The concept of value-added pharmaceuticals has been picked up by different groups of companies, some are aiming to increase willingness to pay for their modified pharmaceutical products, others like generic pharmaceutical producers, try to become more innovative and less ‘patent expiration-dependent’. Optimizing the existing pharmaceuticals can create competitive advantage and can strengthen the reputation and credibility of generic pharmaceutical companies.
Subjects / Keywords
innovation; generic pharmaceutical; value-added
JEL
L65 - Chemicals; Rubber; Drugs; Biotechnology
I12 - Health Behavior

Related items

Showing items related by title and author.

  • Thumbnail
    Where do restaurants come from? The effects of digital platforms on a market niche 
    Eloire, Fabien; Penalva-Icher, Elise; Tubaro, Paola (2021) Communication / Conférence
  • Thumbnail
    The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation 
    Barei, Fereshteh; Le Pen, Claude; Simoens, Steven (2013) Article accepté pour publication ou publié
  • Thumbnail
    Where does complexity come from in the social sciences? Networks, meaning and collective learning in human action 
    Lazega, Emmanuel (2013-06) Communication / Conférence
  • Thumbnail
    Disease Management in the Perspective of Sustainable Growth in Health-Care System: Is Disease Management a Good Business Model for the Sustainability of Health-Care System? 
    Barei, Fereshteh (2015) Chapitre d'ouvrage
  • Thumbnail
    The refinement of the super generic concept: semantic challenge for product re-innovation? 
    Barei, Fereshteh; Ross, Malcolm (2015) Article accepté pour publication ou publié
Dauphine PSL Bibliothèque logo
Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16
Phone: 01 44 05 40 94
Contact
Dauphine PSL logoEQUIS logoCreative Commons logo